Advertisement

News from the European Society of Cardiology Congress — Physician’s First Watch

Medical News |
September 3, 2013

News from the European Society of Cardiology Congress

By the NEJM Journal Watch Editors

This week, NEJM Journal Watch and CardioExchange have been bringing you news and analyses from the European Society of Cardiology Congress in Amsterdam, the Netherlands. Here are some highlights:

SAVOR-TIMI 53 and EXAMINE: In two placebo-controlled trials, the diabetes drugs saxagliptin and alogliptin neither decreased nor increased the incidence of major adverse CV events over roughly 2 years.

Hokusai-VTE: In a noninferiority trial among patients with symptomatic venous thromboembolism, the investigational drug edoxaban had similar efficacy to warfarin, with lower rates of bleeding.

RE-ALIGN: In patients with mechanical heart valves, dabigatran was associated with higher rates of both thrombotic and bleeding events, compared with warfarin.

TASTE: Thrombus aspiration before percutaneous coronary intervention showed no mortality advantage over PCI alone at 30 days in patients with ST-segment-elevation MI.

PRAMI: Restricting revascularization to culprit lesions during primary PCI led to a significantly higher rate of cardiac death, nonfatal MI, or refractory angina.

ACCOAST: Giving prasugrel before coronary angiography was not more efficacious than just-in-time administration and significantly increased bleeding.

For even more conference coverage, visit CardioExchange's ESC.13 Headquarters at the link below.

Your Comment

(will not be published)

Filtered HTML

  • Allowed HTML tags: <a> <em> <strong> <cite> <blockquote> <code> <ul> <ol> <li> <dl> <dt> <dd>
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Do you have any conflict of interest to disclose?
CAPTCHA
This question is for testing whether you are a human visitor and to prevent automated spam submissions.
Image CAPTCHA
Enter the characters shown in the image.

Vertical Tabs

* Required

Reader comments are intended to encourage lively discussion of clinical topics with your peers in the medical community. We ask that you keep your remarks to a reasonable length, and we reserve the right to withhold publication of remarks that do not meet this standard.

PRIVACY: We will not use your email address, submitted for a comment, for any other purpose nor sell, rent, or share your e-mail address with any third parties. Please see our Privacy Policy.

Advertisement
Advertisement
Advertisement